203 related articles for article (PubMed ID: 23462923)
1. Identification of PTHrP(12-48) as a plasma biomarker associated with breast cancer bone metastasis.
Washam CL; Byrum SD; Leitzel K; Ali SM; Tackett AJ; Gaddy D; Sundermann SE; Lipton A; Suva LJ
Cancer Epidemiol Biomarkers Prev; 2013 May; 22(5):972-83. PubMed ID: 23462923
[TBL] [Abstract][Full Text] [Related]
2. Elevation of circulating plasma cytokines in cancer patients with high plasma parathyroid hormone-related protein levels.
Takahashi S; Hakuta M; Aiba K; Ito Y; Horikoshi N; Miura M; Hatake K; Ogata E
Endocr Relat Cancer; 2003 Sep; 10(3):403-7. PubMed ID: 14503917
[TBL] [Abstract][Full Text] [Related]
3. [PTHrP and bone sialoprotein as prognostic markers for developing bone metastases in breast cancer patients].
Loibl S; Königs A; Kaufmann M; Costa SD; Bischoff J
Zentralbl Gynakol; 2006 Dec; 128(6):330-5. PubMed ID: 17213971
[TBL] [Abstract][Full Text] [Related]
4. Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis.
Ali SM; Demers LM; Leitzel K; Harvey HA; Clemens D; Mallinak N; Engle L; Chinchilli V; Costa L; Brady C; Seaman J; Lipton A
Ann Oncol; 2004 Mar; 15(3):455-9. PubMed ID: 14998848
[TBL] [Abstract][Full Text] [Related]
5. Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment.
Chung YC; Ku CH; Chao TY; Yu JC; Chen MM; Lee SH
Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):424-8. PubMed ID: 16537696
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of the serum cross-linked N-telopeptide of type I collagen as a marker of bone metastasis from lung cancer.
Tamiya M; Suzuki H; Kobayashi M; Sasada S; Okamoto N; Morishita N; Yasue T; Matsuura Y; Hirashima T; Kawase I
Med Oncol; 2012 Mar; 29(1):215-8. PubMed ID: 21258879
[TBL] [Abstract][Full Text] [Related]
7. PTHrP(12-48) Modulates the Bone Marrow Microenvironment and Suppresses Human Osteoclast Differentiation and Lifespan.
Kamalakar A; Washam CL; Akel NS; Allen BJ; Williams DK; Swain FL; Leitzel K; Lipton A; Gaddy D; Suva LJ
J Bone Miner Res; 2017 Jul; 32(7):1421-1431. PubMed ID: 28370412
[TBL] [Abstract][Full Text] [Related]
8. Circulating parathyroid hormone-related protein (109-141) in malignancy-associated hypercalcemia.
Nagasaki K; Otsubo K; Kajimura N; Tanaka R; Watanabe H; Tachimori Y; Kato H; Yamaguchi H; Saito D; Watanabe T; Adachi I; Yamaguchi K
Jpn J Clin Oncol; 1996 Feb; 26(1):6-11. PubMed ID: 8551669
[TBL] [Abstract][Full Text] [Related]
9. Parathyroid hormone-related protein (PTHrP)-(1-139) isoform is efficiently secreted in vitro and enhances breast cancer metastasis to bone in vivo.
Guise TA; Yin JJ; Thomas RJ; Dallas M; Cui Y; Gillespie MT
Bone; 2002 May; 30(5):670-6. PubMed ID: 11996903
[TBL] [Abstract][Full Text] [Related]
10. Study on diagnostic value of P1NP and β-CTX in bone metastasis of patients with breast cancer and the correlation between them.
Zuo CT; Yin DC; Fan HX; Lin M; Meng Z; Xin GW; Zhang YC; Cheng L
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5277-5284. PubMed ID: 31298379
[TBL] [Abstract][Full Text] [Related]
11. Is parathyroid hormone-related protein a sensitive serum marker in advanced breast cancer?
Pyke CM; Menezes G; Purdie DM; Johnson S; Cowley D
Aust N Z J Surg; 1997 May; 67(5):256-9. PubMed ID: 9152154
[TBL] [Abstract][Full Text] [Related]
12. Elevated N-telopeptide as a potential diagnostic marker for bone metastasis in lung cancer: A meta-analysis.
Liu B; Zhao Y; Yuan J; Zeng L; Sun R; Meng X; Yang S
PLoS One; 2017; 12(11):e0187860. PubMed ID: 29182642
[TBL] [Abstract][Full Text] [Related]
13. Parathyroid hormone-related peptide in plasma of patients with hypercalcemia and malignant lesions.
Kao PC; Klee GG; Taylor RL; Heath H
Mayo Clin Proc; 1990 Nov; 65(11):1399-407. PubMed ID: 1700240
[TBL] [Abstract][Full Text] [Related]
14. Detection of circulating tumor cells in breast cancer patients using multiplex reverse transcription-polymerase chain reaction and specific primers for MGB, PTHRP and KRT19 correlation with clinicopathological features.
Skondra M; Gkioka E; Kostakis ID; Pissimissis N; Lembessis P; Pectasides D; Koutsilieris M
Anticancer Res; 2014 Nov; 34(11):6691-9. PubMed ID: 25368276
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of prostate specific antigen (PSA), C-terminal propeptide of blood type I procollagen (PICP) and urine type I collagen-crosslinked N telopeptide (NTx) levels using bone scintigraphy in prostate cancer patients.
Fukumitsu N; Uchiyama M; Mori Y; Kishimoto K; Nakada J
Ann Nucl Med; 2003 Jun; 17(4):297-303. PubMed ID: 12932112
[TBL] [Abstract][Full Text] [Related]
16. Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer.
Korpela J; Tiitinen SL; Hiekkanen H; Halleen JM; Selander KS; Väänänen HK; Suominen P; Helenius H; Salminen E
Anticancer Res; 2006; 26(4B):3127-32. PubMed ID: 16886645
[TBL] [Abstract][Full Text] [Related]
17. Establishment of a serological molecular model for the early diagnosis and progression monitoring of bone metastasis in lung cancer.
Teng X; Wei L; Han L; Min D; Du Y
BMC Cancer; 2020 Jun; 20(1):562. PubMed ID: 32546271
[TBL] [Abstract][Full Text] [Related]
18. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis.
Guise TA; Yin JJ; Taylor SD; Kumagai Y; Dallas M; Boyce BF; Yoneda T; Mundy GR
J Clin Invest; 1996 Oct; 98(7):1544-9. PubMed ID: 8833902
[TBL] [Abstract][Full Text] [Related]
19. Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer.
Dean-Colomb W; Hess KR; Young E; Gornet TG; Handy BC; Moulder SL; Ibrahim N; Pusztai L; Booser D; Valero V; Hortobagyi GN; Esteva FJ
Breast Cancer Res Treat; 2013 Jan; 137(2):631-6. PubMed ID: 23242617
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of bone remodeling markers in the diagnosis of bone metastases in patients with breast cancer.
Pectasides D; Farmakis D; Nikolaou M; Kanakis I; Kostopoulou V; Papaconstantinou I; Karamanos NK; Economopoulos T; Raptis SA
J Pharm Biomed Anal; 2005 Feb; 37(1):171-6. PubMed ID: 15664758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
